FDA says AEMS is its new Adverse Event Monitoring System, and the agency also maintains a dedicated page for new safety information or potential signals of serious risks identified through that system. Separately, FDA’s Drug Safety Communications page is updated with current safety announcements, including the recent carbidopa/levodopa vitamin B6 deficiency warning and the GLP-1 labeling update.
Inference: taken together, these tools suggest that regulators are not only collecting safety information more systematically, but also presenting it more visibly and more continuously. That changes the external environment for companies, clinicians, journalists, and patients alike.
For pharmacovigilance teams, the implication is strategic. The question is no longer only “what do we submit?” It is also “what public-facing safety signals are emerging around our products, classes, or competitors, and how quickly are they becoming visible?”
0 Comments